As shown in the flow chart (Figure 1), a prognostic model was constructed based on nine FRLs (CFAP58-DT, LINC00443, EMSLR, HYI-AS1, ADIRF-AS1, LINC02474, CDKN2B-AS1, LINC01629, and LINC00942) that predict the overall survival, tumor immune characteristics, and drug treatment response in UCEC. This evidence concerns the gene CDKN2B and neoplasm.